Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
5.12
-0.13 (-2.48%)
At close: Jan 21, 2025, 4:00 PM
5.22
+0.10 (1.95%)
After-hours: Jan 21, 2025, 5:20 PM EST
Enanta Pharmaceuticals Revenue
In the fiscal year ending September 30, 2024, Enanta Pharmaceuticals had annual revenue of $67.64M, down -14.61%. Enanta Pharmaceuticals had revenue of $14.61M in the quarter ending September 30, 2024, a decrease of -22.84%.
Revenue (ttm)
$67.64M
Revenue Growth
-14.61%
P/S Ratio
1.64
Revenue / Employee
$516,298
Employees
131
Market Cap
108.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ENTA News
- 13 days ago - Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - Business Wire
- 2 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 - Business Wire
- 4 months ago - Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) - Business Wire
- 5 months ago - Enanta Pharmaceuticals to Participate in Investor Conferences in September - Business Wire
- 6 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter - Business Wire